The chemist as astronaut: Searching for biologically useful space in the chemical universe

Biochemical Pharmacology

Volumn 78, Issue 3, 2009, Pages 217-223

  Triggle, David J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Chemical space; Fragment assembly; Natural products; Pharmacological space; Privileged structures; Scaffolds

Indexed keywords

BENZODIAZEPINE; BRYOSTATIN;

ARTICLE; BACTERIAL INFECTION; BIOCHEMISTRY; BIOSYNTHESIS; COSMONAUT; DEGENERATIVE DISEASE; DRUG STRUCTURE; GENETIC ENGINEERING; HUMAN; INFLAMMATION; METHODOLOGY; PAIN; PHARMACOLOGY; PRIORITY JOURNAL; PRODUCTIVITY; STROKE; VIRUS INFECTION;

EID: 67349190954     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.02.015     Document Type: Note

References (74)

1. Business Insights. Drug approval trends at the FDA and EMEA. www.globalbusinessinsights.com. Accessed December 10, 2008.
2. Owens J. Big pharma slims down to increase productivity. Nat Rev Drug Discov 6 (2007) 173-174
3. Hudlicky R.J.W. The way of synthesis (2007), Wiley-VCH, New York
4. Trost B.M., and Dong G. Total synthesis of bryostatin 16 using atom-economical and chemoselective approaches. Nature 456 (2008) 485-488
5. O'Collins V.E., MacLeod M.R., Donnan G.A., Horky L.L., van der Worp B.H., and Howells D.W. 1,026 experimental treatments in acute stroke. Ann Neurol 59 (2006) 467-477
6. Max M.B., and Stewart W.F. The molecular epidemiology of pain: a new discipline for drug discovery. Nat Rev Drug Discov 7 (2008) 647-658
7. Huangfu D., Maehr R., Guo W., Eijkelenboom A., Snitow M., Chen A.E., et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 26 (2008) 795-797
8. Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest 116 (2006) 2837-2842
9. Williams M. Systems and integrative biology as alternative guises for pharmacology: prime time for an iPharm concept. Biochem Pharmacol 70 (2005) 1707-1716
10. Baldi P. Chemoinformatics, drug design, and systems biology. Genome Inf 16 (2005) 281-285
11. Dobson C.M. Chemical space and biology. Nature 432 (2004) 824-828
12. Simon G.M., and Cravatt B.F. Challenges for the "chemical-systems" biologist. Nat Chem Biol 4 (2008) 639-642
13. Koonin E.V., Wolf Y.I., and Karev G.P. The structure of the protein universe and genome evolution. Nature 420 (2002) 218-223
14. Lipinski C., and Hopkins A. Navigating chemical space for biology and medicine. Nature 432 (2004) 855-861
15. Rees M. Just six numbers. The deep forces that shape the universe (2002), Basic Books, New York, NY
16. Dyson F. Disturbing the universe (1979), Harper Row, New York, NY
17. Susskind L. The cosmic landscape. String theory and the illusion of intelligent design (2006), Little, Brown & Company, Boston, New York
18. The Limits of Organic Life in Planetary Systems. Washington, DC: National Academies Press; 2007. www.nap.edu.
19. Lipkus A.H., Yuan Q., Lucas K.A., Funk S.A., Bartelt III W.F., Schenck R.J., et al. Structural diversity of organic chemistry: a scaffold analysis of the CAS Registry. J Org Chem 73 (2008) 4443-4451
20. Bemis G.W., and Murcko M.A. The properties of known drugs. 1. Molecular frameworks. J Med Chem 39 (1996) 2887-2893
21. Bemis G.W., and Murcko M.A. The properties of known drugs. 2. Side chains. J Med Chem 42 (1999) 5095-5099
22. Freedland S.J., and Hurst L.D. The genetic code is one in a million. J Mol Evol 47 (1998) 238-248
23. Turanov A.A., Lobanov A.V., Fomenko D.E., Morrison H.G., Sogin M.L., Klobutcher L.A., et al. Genetic code supports targeted insertion of two amino acids by one codon. Science 323 (2009) 259-261
24. Itzkovitz S., and Alon U. The genetic code is nearly optimal for allowing additional information within protein-coding sequences. Genome Res 17 (2007) 405-412
25. Kazazian Jr. H.H. Mobile elements: drivers of genome evolution. Science 303 (2004) 1626-1632
26. Crick F.H.C. The origin of the genetic code. J Mol Biol 38 (1968) 367-379
27. Davies P. Are aliens among us?. Sci Am (2007) 62-69
28. Russ Ap, and Lampel S. The druggable genome: an update. Drug Discov Today 10 (2005) 1607-1610
29. Paolini G.V., Shapland R.H.B., van Hoorn W.P., Mason J.S., and Hopkins A.L. Nat Biotechnol 24 (2006) 805-815
30. Russell R.B., Sasieni P.D., and Sternberg M.J.E. Supersites within superfolds. Binding site similarity in the absence of homology. J Mol Biol 282 (1998) 903-918
31. Marth J.D. A unified vision of the building blocks of life. Nat Cell Biol 10 (2008) 1015-1016
32. Xie J., and Schultz P.G. Adding amino acids to the genetic repertoire. Curr Opin Chem Biol 9 (2005) 548-554
33. Beene D.L., Dougherty D.A., and Lester H.A. Unnatural amino acid mutagenesis in mapping ion channel function. Curr Opin Neurobiol 13 (2003) 264-270
34. Wang W., Takimoto J.K., Louie G.V., Baiga T.J., Noel J.P., Lee K.-F., et al. Genetically encoding unnatural amino acids foe cellular and neuronal studies. Nat. Neuorsci. 10 (2007) 1063-1072
35. Thornton J.W. Resurrecting ancient genes: experimental analysis of extinct molecules. Nat Rev Genet 5 (2004) 366-375
36. Gaucher E.A., Thomson J.M., Burgan M.F., and Benner S.A. Inferring the palaoeenvironment of ancient bacteria on the basis of resurrected proteins. Nature 425 (2003) 285-288
37. Gibson D.G., Benders G.A., Andrews-Pfannkoch C., Denisova E.A., Baden-Tillson H., Zaeveri J., et al. Complete chemical synthesis, assembly and cloning of a Mycoplasma genitalium genome. Science 319 (2008) 1215-1219
38. Ro D.-K., Paradise E.M., Ouellet M., Fisher K.J., Newman K.L., Ndunga J.M., et al. Production of the antimalarial drug precursor artemesinic acid in engineered yeast. Nature 440 (2006) 940-943
39. Deitsch K.W., Moxon E.R., and Wellems T.E. Shared themes of antigenic variation and virulence in bacterial, protozoal and fungal infections. Microbiol Mol Biol Rev 61 (1997) 281-293
40. Prucca C.G., Slavin I., Quiroga R., Elias E.V., Rivero F.D., Saura A., et al. Antigenic variation in Giardia lambia is regulated by RNA interference. Nature 456 (2008) 750-754
41. Terlau H., and Olivera B.M. Conus venoms: a rich source of novel ion channel-targeted peptides. Physiol Rev 84 (2004) 41-68
42. Olivera B.M. Conus peptides: biodiversity-based discovery and exogenomics. J Biol Chem 281 (2006) 31173-31177
43. Evans B.E., Rittle K.E., Bock M.G., DiPardo R.M., Whitter W.L., Veber D.F., et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 31 (1988) 2235-2246
44. Patchett A.A., and Nargund R.P. Privileged structures-an update. Ann Rep Med Chem 36 (2000) 289-298
45. Ariens E.J. Stereochemistry in the analysis of drug action. Med Res Rev 7 (1987) 367-387
46. Wiley R.A., and Rich D.H. Peptidomimetics derived from natural products. Med Res Rev 13 (1993) 327-384
47. Triggle D.J. The 1,4-dihydropyridine nucleus: a pharmacophoric template. Part 1. Actions at ion channels. Mini Rev Med Chem 3 (2003) 215-223
48. Leeson P.D., and Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6 (2007) 881-890
49. Verdine, GL. The combinatorial chemistry of nature. 1996;384(Suppl.):11-3.
50. Wermuth C.G. Similarity in drugs: reflections on analogue design. Drug Discov Today 11 (2006) 348-354
51. Wermuth C.G. Selective optimization of side activities: another way for drug discovery. J Med Chem 47 (2004) 1303-1314
52. Hong C.R., and Sullivan Jr. D.J. New uses for old drugs. Nature 448 (2007) 645-646
53. Crukhorn S. New targets for old drugs. Nat Rev Drug Discov 7 (2008) 251
54. Campillos M., Kuhn M., Gavin A.-C., Jensen L.J., and Bork P. Drug target identification using side-effect similarity. Science 321 (2008) 263-266
55. Newman D.J., and Cragg G.M. Natural products as sources of new drugs over the past 25 years. J Nat Prod 70 (2007) 461-477
56. Clardy J., and Walsh C. Lessons from natural molecules. Nature 432 (2004) 829-837
57. Schreiber S.L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287 (2000) 1964-1969
58. Morton D., Leach S., Cordier C., Warriner S., and Nelson A. Synthesis of natural-product-like molecules with over eighty distinct scaffolds. Angew Chem Int Ed 48 (2009) 104-109
59. Koch M.A., Schuffenhauer, Scheck M., Wetzel S., Casaulta M., Odermatt A., et al. Charting biologically relevant chemical space: a structural classification of natural products (SCONP). Proc Nat Acad Sci USA 102 (2005) 17272-17277
60. Hajduk P.J., and Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov (2007)
61. Congreve M., Chessari G., Tisi D., and Woodhead A.J.U. Recent developments in fragment-based drug discovery. J Med Chem 51 (2008) 3661-3680
62. Siegel M.G., and Vieth M. Drugs in other drugs: a new look at drugs as fragments. Drug Discov Today (2006)
63. Kolb HC, Sharpless KB. The growing impact of click chemistry on drug discovery. 2003;8:1128-37.
64. Lewis W.G., Green L.G., Grynszpan F., Radic Z., Carlier P.R., Taylor P., et al. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew Chem Int Ed 41 (2002) 1053-1057
65. Travers J., and Milgram S. An experimental study of the small world problem. Sociometry 32 (1969) 425-443
66. Peterson R.T. Chemical biology and the limits of reductionism. Nat Chem Biol 4 (2008) 635-638
67. Williams M. Systems and integrative biology as alternative guises for pharmacology: prime time for an iPharm concept?. Biochem Pharmacol 70 (2005) 1707-1716
68. Ellis R.J. Macromolecular crowding: obvious but unappreciated. Trends Biochem Sci 26 (2001) 597-604
69. Land B., Salpeter E.E., and Salpter M. Kinetic parameters for acetylcholine interaction in intact neuromuscular junctions. Proc Nat Acad Sci USA 78 (1981) 7200-7204
70. Adam G., and Delbrick M. Reduction of dimensionality in biological diffusion processes. In: Rich A., and Davidson N. (Eds). Structural chemistry and molecular biology (1968), W.H. Freeman, San Francisco 198-215
71. Axelrod D., and Wang M.D. Reduction-of-dimensionality kinetics at reaction-limited surface receptors. Biophys J 66 (1994) 588-600
72. Roth B.L., Sheffler D.J., and Kroeze W.K. Magic shotguns versus magic bullets; selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3 (2004) 353-359
73. Bianchi M.T., Pthmanathan J., and Cash S.J. From ion channels to complex networks: magic bullet versus magic shotgun approach to anticonvulsant pharmacotherapy. Med Hypotheses (2008)
74. Hopkins A.L., Mason J.S., and Overington J.P. Can we rationally design promiscuous drugs?. Curr Opin Struct Biol 16 (2006) 127-136